Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

ROTY Edition 1 Volume 81: We Have A Launch Date!

9h seekingalpha
February continues to be our worst month yet, but I focus on positioning the model account for success based on our current plan. (197-0)

Biotechs: Still Well Placed For More Gains

2018-02-20 seekingalpha
Big Pharma has to build out pipelines in new areas, and M&A is a compelling alternative. (719-3)

GLYC / GlycoMimetics, Inc. / Biotechnology Value Fund L P - AMENDMENT NO. 3 TO THE SCHEDULE 13G (Passive Investment)

2018-02-16 sec.gov
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1   GlycoMimetics, Inc.  (Name of Issuer) Common Stock, $0.001 par value  (Title of Class of Securities) 38000Q102  (CUSIP Number) December 31, 2017  (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to de

ROTY Edition 1 Volume 80: Adding To Select Positions And Continuing To Manage Risk

2018-02-16 seekingalpha
I remind readers of our biggest loser to date and why risk management has been key to ROTY`s success. (146-0)

GLYC / GlycoMimetics, Inc. / Biotechnology Value Fund L P - AMENDMENT NO. 3 TO THE SCHEDULE 13G (Passive Investment)

2018-02-15 sec.gov
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1   GlycoMimetics, Inc.  (Name of Issuer) Common Stock, $0.001 par value  (Title of Class of Securities) 38000Q102  (CUSIP Number) December 31, 2017  (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to de

GLYC / GlycoMimetics, Inc. / Redmile Group, LLC - 3G/A (Passive Investment)

2018-02-15 sec.gov
glyc_13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. _)*     Glycomimetics Inc (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 38000Q102 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) ý Rule 13d-1(b) ¨ Rule 13d-1(c) ¨ Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person’s init

GLYC / GlycoMimetics, Inc. / Redmile Group, LLC - 3G/A (Passive Investment)

2018-02-15 sec.gov
glyc_13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. _)*     Glycomimetics Inc (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 38000Q102 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) ý Rule 13d-1(b) ¨ Rule 13d-1(c) ¨ Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person’s init

ROTY Edition 1 Volume 79: Limited Downside Catalysts Vs. Binary Risk

2018-02-14 seekingalpha
We discuss the difference between binary catalysts and those with limited downside, utilizing two recent examples. (166-3)

ROTY Edition 1 Volume 78: Simplify Your Decision-Making And Stick To Guidelines

2018-02-13 seekingalpha
As always, readers are encouraged to do their own due diligence, manage risk appropriately, and avoid blindly following. (313-2)

GLYC / GlycoMimetics, Inc. / FMR LLC / Fidelity - 3G (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 0 GLYCOMIMETICS INC COMMON STOCK Cusip #38000Q102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #38000Q102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,224,466 Item 6: 0 Item 7: 2,838,683 Item 8: 0 Item 9: 2,838,683 Item 11: 8.266% Item 12: HC Cusip #38000Q102 Item 1: Reporting Person - Abigail P.

GLYC / GlycoMimetics, Inc. / FMR LLC / Fidelity - 3G (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 0 GLYCOMIMETICS INC COMMON STOCK Cusip #38000Q102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #38000Q102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,224,466 Item 6: 0 Item 7: 2,838,683 Item 8: 0 Item 9: 2,838,683 Item 11: 8.266% Item 12: HC Cusip #38000Q102 Item 1: Reporting Person - Abigail P.

ROTY Edition 1 Volume 77: Market Turmoil Continues - How To React

2018-02-09 seekingalpha
Recent market volatility is addressed and we discuss in depth how to react while sticking to one´s plan. (192-1)

GLYC / GlycoMimetics, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G (Passive Investment)

2018-02-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* GlycoMimetics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 38000Q102 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder

GLYC / GlycoMimetics, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G (Passive Investment)

2018-02-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* GlycoMimetics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 38000Q102 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder

BRIEF-Glycomimetics Enters Agreement With Hovon To Initiate Study Startup Activities For Planned Clinical Trial Of GMI-1271 And Decitabine

2018-02-08 reuters
* GLYCOMIMETICS ENTERS INTO AGREEMENT WITH HOVON TO INITIATE STUDY STARTUP ACTIVITIES FOR PLANNED CLINICAL TRIAL OF GMI-1271 AND DECITABINE IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE UNFIT FOR CHEMOTHERAPY (20-0)


CUSIP: 38000Q102